|Slideshows|September 10, 2021

The Long Shadow of the Towers

Statistical findings from longitudinal studies of mental health among 9/11 witnesses and first responders.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

ByLeah Kuntz

June 29th 2026

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

ByCarol Rosen, MD

June 22nd 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep in Narcolepsy Type 1

ByElena Koundourakis, PhD

June 17th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Long Shadow of the Towers

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep in Narcolepsy Type 1

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults